Omission of surgery in older women with early breast cancer has an adverse impact on breast cancer‐specific survival.
Published: 22nd May 2018
Authors: S. E. Ward, P. D. Richards, J. L. Morgan, G. R. Holmes, J. W. Broggio, K. Collins et al.
Primary endocrine therapy is used as an alternative to surgery in up to 40 per cent of women with early breast cancer aged over 70 years in the UK. This study investigated the impact of surgery
Cancer registration data for 2002–2010 were obtained from two English regions. A retrospective analysis was performed for women with oestrogen receptor (ER)‐positive disease, using statistical modelling to show the effect of treatment (surgery or primary endocrine therapy) and age and health status on BCSS. Missing data were handled using multiple imputation.
Cancer registration data on 23 961 women were retrieved. After data preprocessing, 18 730 of 23 849 women (78·5 per cent) were identified as having ER‐positive disease; of these, 10 087 (53·9 per cent) had surgery and 8643 (46·1 per cent) had primary endocrine therapy. BCSS was worse in the primary endocrine therapy group than in the surgical group (5‐year BCSS rate 69·4 and 89·9 per cent respectively). This was true for all strata considered, although the difference was less in the cohort with the greatest degree of co‐morbidity. For older, frailer patients the hazard of breast cancer death had less relative impact on overall survival.
BCSS in older women with ER‐positive disease is worse if surgery is omitted. This treatment choice may contribute to inferior cancer outcomes. Selection for surgery on the basis of predicted life expectancy may permit choice of women for whom surgery confers little benefit.Full text
You may also be interested in
Breast‐conserving surgery followed by whole‐breast irradiation offers survival benefits over mastectomy without irradiation.
Authors: J. de Boniface, J. Frisell, L. Bergkvist, Y. Andersson
Notes: RT to lower axilla key?
Is axillary ultrasound imaging necessary for all patients with breast cancer?. BJS 2018; 105: 930-932.
Authors: M. Ahmed, M. Douek
Authors: T. K. Krastev, S. J. Schop, J. Hommes, A. A. Piatkowski, E. M. Heuts, R. R. W. J. van der Hulst et al.
Notes: Lipofilling ok
Risk of recurrence and death in patients with breast cancer after delayed deep inferior epigastric perforator flap reconstruction.
Authors: H. Adam, A. C. Docherty Skogh, Å. Edsander Nord, I. Schultz, J. Gahm, P. Hall et al.
Notes: DIEP is safe
Predictors of complications after direct‐to‐implant breast reconstruction with an acellular dermal matrix from a multicentre randomized clinical trial.
Authors: V. L. Negenborn, R. E. G. Dikmans, M. B. Bouman, H. A. H. Winters, J. W. R. Twisk, P. Q. Ruhé et al.
Notes: Not good for large breast
Population‐based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node‐positive invasive lobular carcinoma of the breast. BJS 2018; 105: 987-995.
Authors: E. Morrow, A. Lannigan, J. Doughty, J. Litherland, J. Mansell, S. Stallard et al.
Notes: Less sensitive in lobular carcinoma
Routine histopathological examination after female‐to‐male gender‐confirming mastectomy. BJS 2018; 105: 885-892.
Authors: S. M. J. Van Renterghem, J. Van Dorpe, S. J. Monstrey, J. Defreyne, K. E. Y. Claes, M. Praet et al.
Notes: The case for
Meta‐analysis of neoadjuvant therapy and its impact in facilitating breast conservation in operable breast cancer. BJS 2018; 105: 469-481.
Authors: A. Karakatsanis, M. K. Tasoulis, F. Wärnberg, G. Nilsson, F. MacNeill
Notes: Still unnecessary mastectomies
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non‐surgical management of triple‐negative breast cancer. BJS 2018; 105: 535-543.
Authors: R. F. D. van la Parra, A. B. Tadros, C. M. Checka, G. M. Rauch, A. Lucci, B. D. Smith et al.
Notes: Ductal carcinoma in situ and microcalcification important
Authors: Z. E. Winters, J. R. Benson
Impact of specialist management on survival from radiation‐associated angiosarcoma of the breast. BJS 2018; 105: 401-409.
Authors: L. Feinberg, A. Srinivasan, J. K. Singh, M. Parry, J. Stevenson, L. Jeys et al.
Notes: Improves outcomes
Minimizing inequality in access to precision medicine in breast cancer by real‐time population‐based molecular analysis in the SCAN‐B initiative. BJS 2018; 105: e158-e168.
Authors: L. Rydén, N. Loman, C. Larsson, C. Hegardt, J. Vallon‐Christersson, M. Malmberg et al.
Notes: Promising Swedish initiative